Core Insights - Chemomab Therapeutics is advancing its clinical-stage monoclonal antibody, nebokitug (CM-101), as a potential treatment for systemic sclerosis (SSc), a severe autoimmune disease lacking approved therapies [1][3][12] - New data supporting nebokitug's efficacy will be presented at the CORA 2025 conference, reinforcing its role in targeting CCL24, a key driver of SSc pathology [1][6][12] Company Overview - Chemomab Therapeutics is focused on developing innovative therapeutics for fibro-inflammatory diseases, with nebokitug being a first-in-class dual activity monoclonal antibody that neutralizes CCL24 [12] - The company has received FDA and EMA Orphan Drug designations for nebokitug in the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis, along with FDA Fast Track status for PSC [12] Disease Context - Systemic sclerosis (SSc) is characterized by extensive tissue fibrosis and microvascular injury, making it one of the most lethal systemic connective tissue diseases, with no approved disease-modifying therapies available [2][8] - Current estimates suggest approximately 100,000 SSc patients in the U.S., predominantly affecting women aged 30 to 50 [8] Clinical Evidence - Extensive preclinical studies indicate that blocking CCL24 with nebokitug reduces inflammatory and fibrotic injuries associated with SSc, including lung, skin, and vascular damage [2][3] - A recent peer-reviewed study found that higher serum CCL24 levels correlate with severe SSc manifestations and predict pulmonary function deterioration [4] Ongoing Research - The upcoming presentation at CORA 2025 will detail a study assessing nebokitug's effects on immune cells in SSc, further validating the therapeutic rationale for targeting CCL24 [3][6] - Positive results from the Phase 2 SPRING trial in PSC have strengthened the rationale for evaluating nebokitug in SSc, demonstrating its dual anti-inflammatory and anti-fibrotic mechanisms [5][12]
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis